Medicare's GLP-1 Bridge Project: Expanding Coverage for Weight Management
In 2003, Congress enacted significant legislative changes to Medicare, notably excluding coverage for weight loss medications due to previous issues with diet pills like fen-phen. Today, glucagon-like peptide-1 receptor agonists (GLP-1 medications) have gained prominence for their medically supported benefits in weight management, reshaping the landscape of healthcare coverage.
This evolution has prompted the Centers for Medicare and Medicaid Services (CMS) to initiate the GLP-1 Bridge project. This temporary initiative assesses whether modifications to Medicare Part D could alleviate health-related expenditures. Running from July 1, 2026, to December 31, 2027, the program will cover medications such as Foundayo, Wegovy, and Zepbound KwikPen. Under this plan, beneficiaries will pay a fixed copayment of $50 monthly, which doesn't count toward their annual out-of-pocket limit, operating outside the conventional Part D framework.
The rising cost of healthcare continues to challenge older adults, particularly those with limited financial resources. Without insurance, GLP-1 medications can cost up to $1,500 monthly, rendering them unattainable for many. While pharmaceutical companies offer some discount programs, these may not significantly alleviate costs. Consequently, the GLP-1 Bridge project aims to increase accessibility to these vital medications.
Obesity-related health issues, including hypertension, diabetes, and cardiovascular diseases, threaten the quality of life for seniors. Users of GLP-1 medications have shown substantial weight loss, ranging from 15% to 20% of their total body weight, and reported decreased risks of stroke and heart attacks. Additionally, these drugs have been linked to improved management of cholesterol, blood pressure, and chronic kidney conditions, as well as reduced inflammation, potentially lowering risks of dementia, arthritis, and sleep apnea.
Eligibility for the GLP-1 Bridge project requires an obesity diagnosis based on body mass index (BMI) and a commitment to diet and exercise. Participants must be at least 18 years old and meet specific criteria. Those receiving GLP-1 medications through Medicare Part D, or who seek treatment for conditions other than obesity, may not qualify for this program but may remain eligible under standard Medicare coverage.
This national effort encourages interested individuals to consult healthcare providers about their eligibility and the potential benefits and risks of GLP-1 treatments. Providers must secure prior authorization from CMS for prescribed medications in this program. Notably, while Medicare offers this coverage, Medicaid, including the Oregon Health Plan, does not cover weight loss prescriptions for GLP-1 medications, highlighting differences in regulatory compliance requirements across insurers.